VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced the closing of the acquisition of the epigenetic reagent company Octamer GmbH (“Octamer”) by its subsidiary Belgian Volition SPRL for approximately $725,000, consisting of cash and shares of restricted common stock of Volition. This strategic acquisition helps secure the supply of one of the key components of Volition’s Nu.Q(TM) tests, the recombinant nucleosome used as the calibrant.
Read the full article: VolitionRx Completes Acquisition of Octamer GmbH //
Source: https://www.prnewswire.com/news-releases/volitionrx-completes-acquisition-of-octamer-gmbh-300984851.html